RLS1
MCID: RST012
MIFTS: 33

Restless Legs Syndrome 1 (RLS1)

Categories: Mental diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Restless Legs Syndrome 1

MalaCards integrated aliases for Restless Legs Syndrome 1:

Name: Restless Legs Syndrome 1 57 70
Restless Legs Syndrome, Susceptibility to, 1 57 20 13
Ekbom Syndrome 57 73
Rls1 57 20
Acromelalgia, Hereditary 57
Restless Legs Syndrome 70

Characteristics:

OMIM®:

57 (Updated 05-Apr-2021)
Inheritance:
autosomal dominant

Miscellaneous:
onset in childhood, adolescence, and adulthood
usually progressive
affects up to 10% of the population
associated with iron deficiency anemia
associated with hemodialysis
genetic heterogeneity (see rls2, )


HPO:

31
restless legs syndrome 1:
Inheritance autosomal dominant inheritance heterogeneous


Classifications:



External Ids:

OMIM® 57 102300
OMIM Phenotypic Series 57 PS102300
MedGen 41 C1876177
UMLS 70 C0035258 C3888109

Summaries for Restless Legs Syndrome 1

OMIM® : 57 Restless legs syndrome (RLS) is a neurologic sleep/wake disorder characterized by uncomfortable and unpleasant sensations in the legs that appear at rest, usually at night, inducing an irresistible desire to move the legs. The disorder results in nocturnal insomnia and chronic sleep deprivation (Bonati et al., 2003). (102300) (Updated 05-Apr-2021)

MalaCards based summary : Restless Legs Syndrome 1, also known as restless legs syndrome, susceptibility to, 1, is related to restless legs syndrome and restless legs syndrome 2, and has symptoms including seizures, tremor and back pain. An important gene associated with Restless Legs Syndrome 1 is RLS1 (Restless Legs Syndrome, Susceptibility To). The drugs Celecoxib and Tramadol have been mentioned in the context of this disorder. Affiliated tissues include spinal cord, cortex and liver, and related phenotypes are myoclonus and paresthesia

Wikipedia : 73 Ekbom syndrome may refer... more...

Related Diseases for Restless Legs Syndrome 1

Graphical network of the top 20 diseases related to Restless Legs Syndrome 1:



Diseases related to Restless Legs Syndrome 1

Symptoms & Phenotypes for Restless Legs Syndrome 1

Human phenotypes related to Restless Legs Syndrome 1:

31
# Description HPO Frequency HPO Source Accession
1 myoclonus 31 HP:0001336
2 paresthesia 31 HP:0003401
3 insomnia 31 HP:0100785
4 restless legs 31 HP:0012452
5 exercise-induced leg cramps 31 HP:0008991

Symptoms via clinical synopsis from OMIM®:

57 (Updated 05-Apr-2021)
Neurologic Central Nervous System:
myoclonus
irresistible desire to move the legs
upper extremities may be involved
associated with paresthesias and dysesthesias
relief with motor activation
more
Laboratory Abnormalities:
decreased csf ferritin despite normal serum ferritin levels
increased csf transferrin despite normal serum transferrin levels

Muscle Soft Tissue:
leg cramps may occur with exercise

Clinical features from OMIM®:

102300 (Updated 05-Apr-2021)

UMLS symptoms related to Restless Legs Syndrome 1:


seizures; tremor; back pain; headache; syncope; excessive daytime somnolence; pain; chronic pain; sciatica; snoring; sleep disturbances; vertigo/dizziness; sleeplessness

Drugs & Therapeutics for Restless Legs Syndrome 1

Drugs for Restless Legs Syndrome 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 156)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
2
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
3
Acetaminophen Approved Phase 4 103-90-2 1983
4
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
5
Iron Approved Phase 4 7439-89-6 23925 29936
6
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
7
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
8
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
9
Sumatriptan Approved, Investigational Phase 4 103628-46-2 5358
10
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
11
Amitriptyline Approved Phase 4 50-48-6 2160
12
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
13
Clopidogrel Approved Phase 4 113665-84-2, 120202-66-6 60606
14
Rivastigmine Approved, Investigational Phase 4 123441-03-2 77991
15
Rizatriptan Approved Phase 4 145202-66-0, 144034-80-0 5078
16
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
17
Zolmitriptan Approved, Investigational Phase 4 139264-17-8 441240 60857
18
Donepezil Approved Phase 4 120014-06-4 3152
19
Propranolol Approved, Investigational Phase 4 525-66-6 4946
20
Memantine Approved, Investigational Phase 4 19982-08-2 4054
21
Topiramate Approved Phase 4 97240-79-4 5284627
22
Levetiracetam Approved Phase 4 102767-28-2 441341
23
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
24
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
25
Promethazine Approved, Investigational Phase 4 60-87-7 4927
26
Diphenhydramine Approved, Investigational Phase 4 58-73-1, 147-24-0 3100
27
Suvorexant Approved, Investigational Phase 4 1030377-33-3
28
Parathyroid hormone Approved, Investigational Phase 4 9002-64-6
29
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
30
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
31
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
32 Cyclooxygenase 2 Inhibitors Phase 4
33 Analgesics, Non-Narcotic Phase 4
34 Antirheumatic Agents Phase 4
35 Cyclooxygenase Inhibitors Phase 4
36 Anti-Inflammatory Agents Phase 4
37 Sodium Potassium Chloride Symporter Inhibitors Phase 4
38 diuretics Phase 4
39 Anti-Inflammatory Agents, Non-Steroidal Phase 4
40 Hypoglycemic Agents Phase 4
41 Cardiotonic Agents Phase 4
42 Sympathomimetics Phase 4
43 Omega 3 Fatty Acid Phase 4
44 Amitriptyline, perphenazine drug combination Phase 4
45 Methylprednisolone Acetate Phase 4
46 Duloxetine Hydrochloride Phase 4
47 Iron Supplement Phase 4
48 Hypnotics and Sedatives Phase 4
49 Trace Elements Phase 4
50 Nutrients Phase 4

Interventional clinical trials:

(show top 50) (show all 193)
# Name Status NCT ID Phase Drugs
1 Effects of Gabapentin Enacarbil on Intensity of Cortical Arousal, Heart Rate, Blood Pressure and Anterior Tibialis EMG Responses Associated With PLMs During Sleep in Patients With RLS Using a Novel Computer Assisted Scoring System Unknown status NCT02424695 Phase 4 Gabapentin Enacarbil (GEn);Placebo
2 A Prospective, Randomized Study Evaluating the Efficacy and Safety of Early Diuresis Following Colorectal Surgery Completed NCT02351934 Phase 4 Furosemide;Celecoxib;Gabapentin
3 Exploratory Study of the Efficacy, Practicability and Safety of Intravenous Iron Supplementation Therapy in Moderate to Severe Restless Legs Syndrome With Iron Deficiency or Anaemia in the 3rd Trimester of Pregnancy Completed NCT01245777 Phase 4 ferric carboxymaltose
4 A Method to Switch From Oral Dopamine Agonists to Rotigotine in Patients With Restless Legs Syndrome Completed NCT01976871 Phase 4 Rotigotine
5 Gabapentin as an Adjunct for Pain Management During Dilation and Evacuation: A Double-blind Randomized Controlled Trial Completed NCT03635905 Phase 4 Gabapentin;Placebo
6 A Phase IV Randomised, Double-blind, Active and Placebo-controlled, 6-week Trial to Investigate the Efficacy and Safety of a Starting (and Fixed) Dose 0.25 mg Pramipexole (Mirapex®) in Patients With Idiopathic Restless Legs Syndrome Completed NCT00375284 Phase 4 Pramipexole
7 A 12-Week, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group, Flexible Dose Polysomnography Study of Ropinirole Controlled Release for Restless Legs Syndrome (RLS) in RLS Patients With Sleep Disturbance and Periodic Limb Movements (PLM) During Sleep Completed NCT00373542 Phase 4 ropinirole CR-RLS
8 A Phase IV Randomised, Double-blind, Placebo-controlled, Dose Titration Trial With 0.125-0.75 mg/Day Pramipexole (Sifrol®, Mirapexin®) Orally for 12 Weeks to Investigate the Safety and Efficacy in Out-patients With Idiopathic Restless Legs Syndrome Associated With Mood Disturbances Completed NCT00356096 Phase 4 pramipexole
9 An Open-Label Prospective Study of Restless Legs Patients Switched to Ropinirole From Pramipexole to Help Determine the Equipotent Dose Completed NCT00344994 Phase 4 pramipexole
10 A Parallel Group Study to Evaluate the Efficacy and Safety of Ropinirole for 26 Weeks and to Further Evaluate the Incidence of Augmentation and Rebound for a Further 40 Weeks Open-label Extension Treatment Period in Subjects Suffering From Moderate to Severe Restless Legs Syndrome. Completed NCT00329602 Phase 4 Placebo;Ropinirole
11 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Determine the Effacy and Safety of Topiramate in Subjects With Restless Legs Syndrome (RLS) Completed NCT00200941 Phase 4 Topiramate
12 Effect of Rotigotine Patch Treatment on Cardiovascular Markers in Idiopathic Restless Legs Syndrome : a Pilot Randomized, Placebo-controlled Study Completed NCT01823770 Phase 4 Rotigotine;Placebo patchs
13 Gabapentin Enacarbil Post-marketing Clinical Study A Randomized, Double-blind, Placebo-controlled, Parallel-group Study in Subjects With Restless Legs Syndrome. Completed NCT03053427 Phase 4 Placebo;Gabapentin enacarbil
14 Multicenter, Double-Blind, Placebo-Controlled, Two-Arm, Randomized, Parallel, Treatment Intervention, Sleep Lab Phase 4 Study to Assess the Effect of Rotigotine on Nocturnal Blood Pressure in Patients With Idiopathic Restless Legs Syndrome Completed NCT01455012 Phase 4 Rotigotine;Placebo
15 A Phase IV Randomised, Double-blind, Placebo-controlled, Dose Titration Trial With Pramipexole (Sifrol®, Mirapexin®) 0.125-0.75 mg/Day Per os for 12 Weeks to Investigate the Effects on RLS Symptoms (IRLS) and Sleep Disturbance (MOS Sleep Scale) in Out-patients With Idiopathic Restless Legs Syndrome Completed NCT00349531 Phase 4 Pramipexole
16 A Phase IV Randomised, Double-blind, Placebo-controlled, Dose Titration Trial With Pramipexole (Sifrol, Mirapexin) 0.125-0.75 mg/Day Per os to Investigate the Long-term Efficacy, Safety and Tolerability in Patients With Idiopathic Moderate to Severe Restless Legs Syndrome for 26 Weeks Followed by a 26 Week Open-label Extension Treatment Period Completed NCT00472199 Phase 4 Pramipexole;Placebo
17 Post-marketing Clinical Study of Gabapentin Enacarbil -Non-blinded Study in Restless Legs Syndrome (RLS) Patients With Moderate Renal Impairment- Completed NCT01981941 Phase 4 Gabapentin enacarbil
18 Autonomic Function and Cardiovascular Risk in Restless Legs Syndrome: AUTOREST, a Case-control Study and a Randomized, Double-blind, Placebo-controlled, Parallel-group, 4-week, Multicenter Study of 0.25mg Pramipexole vs. Placebo in Patients With RLS Completed NCT02025608 Phase 4 Pramipexole;Placebo
19 A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose, Parallel-Group Study to Compare the Efficacy, Tolerability, and Safety of 3 Doses of Gabapentin Enacarbil (GSK1838262) With Placebo in the Treatment of Subjects With Moderate-to-Severe Primary Restless Legs Syndrome (RLS) Completed NCT01668667 Phase 4 GSK1838262 600 mg;GSK1838262 450 mg;GSK1838262 300 mg;GSK1838262 Placebo match
20 A Randomized Controlled Trial of Pramipexole for Restless Leg Syndrome in Peritoneal Dialysis Patients Recruiting NCT03817554 Phase 4 Pramipexole
21 Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease Recruiting NCT03082755 Phase 4 Gabapentin Enacarbil;Placebo Oral Tablet
22 A Multicenter Open-Label Extension Study to Evaluate the Efficacy and Safety of HORIZANT (Gabapentin Enacarbil) Extended-Release Tablets in Adolescents Aged 13 to 17 Years Old With Moderate-to-Severe Primary Restless Legs Syndrome Active, not recruiting NCT02633683 Phase 4 HORIZANT 600 mg
23 Quality Improvement and Practice Based Research in Neurology Using the Electronic Medical Record Enrolling by invitation NCT02670161 Phase 4 Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description)
24 Optimum Frequency and Timing of Oral Iron Administration for Childhood Restless Leg Syndrome/Periodic Limb Movement Disorder Enrolling by invitation NCT04610827 Phase 4 Ferrous sulfate
25 Efficacy of Suvorexant in Patients With Effectively Treated Restless Legs Syndrome and Persistent Chronic Insomnia: A Randomized Placebo-Controlled Crossover Trial Not yet recruiting NCT04706091 Phase 4 Suvorexant
26 Evaluation of Cholecalciferol Supplementation in Chronic Kidney Disease Patients With Restless Leg Syndrome Suspended NCT03063190 Phase 4 Vitamin D;Placebo Oral Tablet
27 Blinded, Randomized Study of Gabapentin (Neurontin®) and Gabapentin Enacarbil (Horizant™) in Restless Leg Syndrome Terminated NCT02117076 Phase 4 Gabapentin immediate release;Gabapentin enacarbil extended release
28 Pregabalin (Lyrica) for the Treatment of Restless Legs Syndrome Withdrawn NCT00584246 Phase 4 Pregabalin (Lyrica);Placebo
29 Butrans for Treatment of Restless Legs Syndrome Withdrawn NCT02138357 Phase 4 buprenorphine transdermal delivery system (BTDS);Placebo for BTDS patch
30 Vitamin D in the Treatment of Primary Restless Legs Syndrome: 12 Weeks, Triple-blinded, Randomized, Placebo-controlled Trial Unknown status NCT02256215 Phase 2, Phase 3 Vitamin D
31 A Double-Blinded, Multi-Center, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injectafer (Ferric Carboxymaltose) in the Treatment of Restless Legs Syndrome (RLS) Unknown status NCT02397057 Phase 3 Injectafer
32 A Multicenter 3:1-randomized Placebo-controlled Double-blind Phase IIIb Study on the Effects of Ropinirole on Mood/(Subclinical) Depression in the Therapy of Patients With Moderate to Severe Idiopathic RLS in Germany Completed NCT00357097 Phase 3 Ropinirole
33 High Dose Intravenous Iron in Blood Donors With Iron Deficiency: a Randomized, Controlled Trial Completed NCT01787526 Phase 3 ferric carboxymaltose;oral iron
34 Swiss Restless Legs Syndrome Trial (SRLS) A Double-blind, Randomised, Crossover Trial Investigating the Efficacy and Safety of the Dopamine Agonist Pramipexole (Sifrol®, 0.25-0.75 mg Per Day) Versus Levodopa / Benserazide (Madopar® DR, 125-375 mg Per Day) in Patients With Restless Legs Syndrome Completed NCT00144209 Phase 3 pramipexole;levodopa in combination with benserazide
35 Transdermal Lisuride: a Double-blind, Randomized, Active- and Placebo-controlled Multi-centre Phase III Efficacy Trial for the Treatment of Patients With Restless Legs Syndrome (RLS) Completed NCT00367822 Phase 3 Lisuride;Ropinirole;Placebo
36 A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of XP13512 in Patients With Restless Legs Syndrome. Completed NCT00365352 Phase 3 XP13512 600MG;XP13512 1200MG;PLACEBO
37 A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of XP13512 in Patients With Restless Legs Syndrome. Completed NCT00298623 Phase 3 XP13512 (GSK1838262)
38 A 12-Week, Double-Blind, Placebo Controlled, Parallel Group Study to Assess the Efficacy and Safety of Ropinirole XR (Extended Release) in Patients With Restless Legs Syndrome Completed NCT00197080 Phase 3 Ropinirole Extended Release (XR)
39 A Multi-center, Randomized, Double-blind, Placebo-controlled, Four-arm Parallel-group Trial to Investigate the Efficacy and Safety of Three Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Leg Syndrome Completed NCT00136045 Phase 3 Rotigotine
40 A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Five-Arm Parallel-Group Trial to Investigate the Efficacy and Safety of Four Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Legs Syndrome Completed NCT00135993 Phase 3 Rotigotine
41 A Phase 3 Multi-Center, Placebo-Controlled, Double Blind, 3-Armed Parallel Group, Comparative Study of SPM 962 4.5 and 6.75 mg/Day to Investigate Superiority to Placebo in Patients With Restless Legs Syndrome Completed NCT01084551 Phase 3 SPM 962;SPM 962;Placebo of SPM 962
42 A 12-Week, Double-Blind, Placebo Controlled, Parallel Group Study to Assess the Efficacy and Safety of Ropinirole in Patients Suffering From Restless Legs Syndrome (RLS) Completed NCT00363857 Phase 3 Ropinirole
43 An Open-Label Extension Trial to Investigate the Safety and Tolerability of Long-Term Treatment With Transdermal Rotigotine in Subjects With Idiopathic Restless Legs Syndrome Completed NCT00263068 Phase 3 Rotigotine
44 A Randomized, Double-blind, Placebo-controlled, Parallel Group Clinical Trial Comparing Fixed Doses of 0.25 mg, 0.50 mg and 0.75 mg Pramipexole (Mirapex®) Administered Orally to Investigate the Safety and Efficacy in Patients With Idiopathic Restless Legs Syndrome for 12 Weeks Completed NCT00133198 Phase 3 Pramipexole
45 A Randomised, Double-blind Study to Evaluate the Efficacy and Safety of Pramipexole at Fixed Doses of 0.25 mg, 0.5 mg, and 0.75 mg in Patients With Idiopathic Restless Legs Syndrome for 6 Weeks, Followed by a 46-week Open-label Long-term Study Completed NCT00390689 Phase 3 Pramipexole 0.125 mg tablet;Pramipexole 0.5 mg tablet
46 A 52-Week, Open-Label Study to Assess the Long-Term Safety of Ropinirole Extended Release (XR) in Patients With Restless Legs Syndrome (RLS) Completed NCT00355641 Phase 3 Ropinirole Extended Release (XR)
47 An Open-Label, 52-Week Extension Study Assessing XP13512 Safety and Efficacy in Patients With Restless Legs Syndrome. Completed NCT00333359 Phase 3 XP13512 (GEn)
48 A 12-Week, Randomized, Double-Blind, Parallel Group, Multicentre Study to Assess the Tolerability and Clinical Benefits of Ropinirole Extended Release (XR) Tablets Compared With Ropinirole Immediate Release (IR) Tablets in Subjects With Restless Legs Syndrome (RLS) Completed NCT00314860 Phase 3 ropinirole Extended Release (XR)
49 A 12-week, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Intermittent Dosing of Ropinirole in Patients With Restless Legs Syndrome (RLS) Completed NCT00225862 Phase 3 ropinirole
50 An Open-label Extension Trial to Investigate the Safety and Tolerability of Long-term Treatment With Transdermal Rotigotine in Subjects With Idiopathic Restless Legs Syndrome Completed NCT00498108 Phase 3 Rotigotine

Search NIH Clinical Center for Restless Legs Syndrome 1

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Carbamazepine
Clonazepam

Genetic Tests for Restless Legs Syndrome 1

Anatomical Context for Restless Legs Syndrome 1

MalaCards organs/tissues related to Restless Legs Syndrome 1:

40
Spinal Cord, Cortex, Liver, Cingulate Cortex, Brain

Publications for Restless Legs Syndrome 1

Articles related to Restless Legs Syndrome 1:

(show all 49)
# Title Authors PMID Year
1
Restless legs syndrome: confirmation of linkage to chromosome 12q, genetic heterogeneity, and evidence of complexity. 61 57
15824258 2005
2
Transient RLS during pregnancy is a risk factor for the chronic idiopathic form. 57
21135386 2010
3
Family study of restless legs syndrome in Quebec, Canada: clinical characterization of 671 familial cases. 57
20457962 2010
4
Restless legs syndrome with periodic limb movements: a possible cause of idiopathic hyperCKemia. 57
19704085 2009
5
Replication of restless legs syndrome loci in three European populations. 57
19279021 2009
6
Restless legs syndrome: an update on genetics and future perspectives. 57
18070136 2008
7
Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions. 57
17637780 2007
8
Canadian restless legs syndrome twin study. 57
17485653 2007
9
Nocturnal blood pressure changes in patients with restless legs syndrome. 57
17420405 2007
10
Pathologic gambling in patients with restless legs syndrome treated with dopaminergic agonists. 57
17242339 2007
11
Genetics of restless legs syndrome. 57
16624598 2006
12
Evidence for further genetic locus heterogeneity and confirmation of RLS-1 in restless legs syndrome. 57
16124010 2006
13
Restless legs syndrome and attention-deficit/hyperactivity disorder. 57
16049930 2005
14
Restless legs syndrome: a community-based study of prevalence, severity, and risk factors. 57
15955944 2005
15
Effective cabergoline treatment in idiopathic restless legs syndrome. 57
15623686 2004
16
Childhood-onset restless legs syndrome. 57
15505786 2004
17
Restless legs syndrome and pregnancy. 57
15452299 2004
18
Decreased transferrin receptor expression by neuromelanin cells in restless legs syndrome. 57
15136682 2004
19
Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome. 57
12913188 2003
20
Autosomal dominant restless legs syndrome maps on chromosome 14q. 57
12764067 2003
21
Clinical practice. Restless legs syndrome. 57
12761367 2003
22
Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. 57
14592341 2003
23
Complex segregation analysis of restless legs syndrome provides evidence for an autosomal dominant mode of inheritance in early age at onset families. 57
12205641 2002
24
Mode of inheritance and susceptibility locus for restless legs syndrome, on chromosome 12q. 57
12068378 2002
25
Evidence for a genetic association between monoamine oxidase A and restless legs syndrome. 57
12136060 2002
26
Identification of a major susceptibility locus for restless legs syndrome on chromosome 12q. 57
11704926 2001
27
MRI measurement of brain iron in patients with restless legs syndrome. 57
11160969 2001
28
Restless legs syndrome in monozygotic twins: clinical correlates. 57
11087794 2000
29
Abnormalities in CSF concentrations of ferritin and transferrin in restless legs syndrome. 57
10762522 2000
30
Clinical symptoms and possible anticipation in a large kindred of familial restless legs syndrome. 57
8813218 1996
31
Augmentation of the restless legs syndrome with carbidopa/levodopa. 57
8723377 1996
32
Myoclonus in familial restless legs syndrome. 57
1267623 1976
33
Restless legs syndrome. 57
13726241 1960
34
Sudden bodily jerks on falling asleep. 57
13651496 1959
35
Hereditary acromelalgia or restless legs. 57
13469127 1957
36
The genetic basis for the evolution of soma: mechanistic evidence for the co-option of a stress-induced gene into a developmental master regulator. 61
33259762 2020
37
Pregabalin-associated movement disorders: A literature review. 61
33033779 2020
38
Genotype-matched Newcastle disease virus vaccine confers improved protection against genotype XII challenge: The importance of cytoplasmic tails in viral replication and vaccine design. 61
31725727 2019
39
Knocking Out the Gene RLS1 Induces Hypersensitivity to Oxidative Stress and Premature Leaf Senescence in Rice. 61
30241349 2018
40
Development of a novel Newcastle disease virus (NDV) neutralization test based on recombinant NDV expressing enhanced green fluorescent protein. 61
29169354 2017
41
A novel protein RLS1 with NB-ARM domains is involved in chloroplast degradation during leaf senescence in rice. 61
21980143 2012
42
Childhood-onset restless legs syndrome: clinical and genetic features of 22 families. 61
18381645 2008
43
Suggestive evidence for linkage for restless legs syndrome on chromosome 19p13. 61
18193462 2008
44
Genetic association studies of neurotensin gene and restless legs syndrome in French Canadians. 61
17644423 2008
45
Variants in the neuronal nitric oxide synthase (nNOS, NOS1) gene are associated with restless legs syndrome. 61
18058820 2008
46
Evidence for linkage of restless legs syndrome to chromosome 9p: are there two distinct loci? 61
18032746 2008
47
Molecular genetic studies of DMT1 on 12q in French-Canadian restless legs syndrome patients and families. 61
17510944 2007
48
Family-based association study of the restless legs syndrome loci 2 and 3 in a European population. 61
17133505 2007
49
Genetic aspects of restless legs syndrome. 61
17068272 2006

Variations for Restless Legs Syndrome 1

Expression for Restless Legs Syndrome 1

Search GEO for disease gene expression data for Restless Legs Syndrome 1.

Pathways for Restless Legs Syndrome 1

GO Terms for Restless Legs Syndrome 1

Sources for Restless Legs Syndrome 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....